Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19
TechCrunch
NOVEMBER 23, 2020
According to a statement, the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins. RESILIENCE will enable these solutions by combining cutting edge technology, an unrivaled pool of talent, and the industry’s first shared service business model.
Let's personalize your content